Thrombin Generation Assay to Support Hematologists in the Era of New Hemophilia Therapies
International Journal of Laboratory Hematology · 2025
DOI: 10.1111/ijlh.14406 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Laboratory Hematology, 2025. Verfasst von Laurie Josset und 2 weiteren Autor:innen. Beteiligte Einrichtung: Universite Claude Bernard Lyon 1, UR4609 - Hemostase & Thrombose, Lyon, France. Hauptthemen laut MEDLINE: Hemophilia A, Thrombin. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Hematology laboratories have traditionally monitored hemophilia replacement therapy by measuring coagulation factors before and after infusion. However, new drugs that do not rely on the replacement of the deficient factor require new approaches to laboratory monitoring, as factor VIII (FVIII) or factor IX (FIX) assays are no longer adequate. Non‐factor therapies come in many different forms, that have one thing in common: they all increase thrombin generation. Their main adverse effect is thrombosis which may occur when too much thrombin is formed. This is the perfect mirror image of anticoagulant treatment, which always diminishes the amount of thrombin formed and has bleeding as its main adverse effect. Thrombin‐forming capacity is decreased in congenital bleeding disorders and increased in prothrombotic conditions, indicating it governs bleeding and thrombosis. Therefore, the thrombin generation assay (TGA) is a logical tool for monitoring non‐factor therapies, offering a comprehensive assessment of hemostatic balance. TGA identifies patients with severe bleeding, helps to optimize bypassing therapy, and detects hypercoagulability, making it ideal for guiding and monitoring hemophilia treatment with non‐factor therapies. It also assesses the efficacy and safety of combined therapies, including non‐factor therapies with bypassing agents or FVIII/FIX concentrates. The purpose of this paper is to review the current state of knowledge regarding the use of TGA to monitor novel hemophilia therapies. It will address controversies, limitations, and knowledge gaps related to the integration of TGA into personalized medicine in routine clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Universite Claude Bernard Lyon 1, UR4609 - Hemostase & Thrombose, Lyon, France.
- Unite d'Hemostase Clinique, Centre de Référence de l'Hémophilie, Hopital Cardiologique Louis Pradel, Hospices Civils de Lyon, Lyon, France.
ORCID-Profile: Yesim Dargaud
Zitieren
APA
Josset, L., Rezigue, H., & Dargaud, Y. (2025). Thrombin Generation Assay to Support Hematologists in the Era of New Hemophilia Therapies. International Journal of Laboratory Hematology. https://doi.org/10.1111/ijlh.14406
Vancouver
Josset L, Rezigue H, Dargaud Y. Thrombin Generation Assay to Support Hematologists in the Era of New Hemophilia Therapies. International Journal of Laboratory Hematology. 2025. doi:10.1111/ijlh.14406
BibTeX
@article{Josset2025,
author = {Josset, Laurie and Rezigue, Hamdi and Dargaud, Yesim},
title = {Thrombin Generation Assay to Support Hematologists in the Era of New Hemophilia Therapies},
journal = {International Journal of Laboratory Hematology},
year = {2025},
doi = {10.1111/ijlh.14406}
}
EUVIMED